NMPA Registration & Manufacturing License Support for China
The NMPA (National Medical Products Administration) governs registration and approval of medical devices in China. MTL guides international manufacturers through every step of the process — from initial regulatory pathway assessment to final approval.
How NMPA Registration Works
The NMPA process involves several stages that run in sequence, with manufacturing license applications proceeding in parallel where required:
Product Classification
Your device is classified by NMPA into a risk category, which determines the depth of technical documentation and whether clinical evaluation or a clinical trial is required.
Technical Documentation
Preparation of the technical file — product specifications, testing reports, and supporting evidence — to NMPA's documentation standards.
Clinical Evaluation / Trial Coordination
Depending on classification, either a clinical evaluation report or a coordinated clinical trial is prepared to support the submission.
Formal Submission & Manufacturing License
The registration application is submitted to NMPA; where a domestic manufacturing license is also required, that application is coordinated in parallel.
How Megalith Guides You Through It
MTL guides international clients through every step — from initial regulatory pathway assessment through to final approval — working alongside established local regulatory affairs specialists. Because the depth of documentation and evidence required depends heavily on your device's risk classification, MTL starts by assessing your specific product against NMPA's classification framework so you have a realistic view of the pathway ahead before committing resources.
Registration and manufacturing licensing are frequently linked to Megalith's other services — once a product is NMPA-registered, it can move directly into CDMO-facilitated manufacturing and Megalith's nationwide distribution network.
Frequently Asked Questions
How does the NMPA registration and licensing process work in China?
The NMPA (National Medical Products Administration) governs the registration and approval of medical devices in China. The process involves product classification, preparation of technical documentation, clinical evaluation or clinical trial coordination, and formal submission to NMPA. Manufacturing license applications run in parallel where required. MTL guides international clients through every step — from initial regulatory pathway assessment to final approval — working alongside established local regulatory affairs specialists.
Does the registration pathway differ by device type?
Yes. NMPA classifies medical devices into different risk categories, and the registration pathway — including how much technical documentation is required and whether clinical evaluation or a clinical trial is needed — varies by classification. MTL assesses your specific product's classification early in the engagement so you have realistic timeline and documentation expectations from the outset.
What happens after NMPA registration is approved?
Once a product achieves NMPA registration, manufacturers typically move into commercial execution — arranging manufacturing (directly or via a CDMO partner), and activating distribution through Megalith's nationwide hospital, clinic, university, and distributor network.
Related Services
Ready to Discuss Your China Market Entry?
Tell us about your product and goals — MTL typically responds within one business day.
Contact Megalith Technology →